NEW YORK — Centogene said on Thursday that it has received Emergency Use Authorization from the US Food and Drug Administration for a PCR-based SARS-CoV-2 test.
According to Centogene, the test is designed to detect the virus in oropharyngeal swab specimens and may only be performed at the Rostock, Germany-based company's CLIA-certified lab.
Earlier this month Centogene said that previously acquired laboratory space in Hamburg is now exclusively performing SARS-CoV-2 testing with a capacity of more than 5,000 tests a day.